| Chimeric antigen receptor T cells in refractory B-cell lymphomas SJ Schuster, J Svoboda, EA Chong, SD Nasta, AR Mato, Ö Anak, ... New England Journal of Medicine 377 (26), 2545-2554, 2017 | 2112 | 2017 |
| Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis AR Mato, C Nabhan, MC Thompson, N Lamanna, DM Brander, B Hill, ... Haematologica 103 (5), 874, 2018 | 524 | 2018 |
| Lenalidomide plus rituximab as initial treatment for mantle-cell lymphoma J Ruan, P Martin, B Shah, SJ Schuster, SM Smith, RR Furman, P Christos, ... New England Journal of Medicine 373 (19), 1835-1844, 2015 | 305 | 2015 |
| Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy M Smith, A Dai, G Ghilardi, KV Amelsberg, SM Devlin, R Pajarillo, ... Nature medicine 28 (4), 713-723, 2022 | 303 | 2022 |
| Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma P Armand, S Rodig, V Melnichenko, C Thieblemont, K Bouabdallah, ... Journal of Clinical Oncology 37 (34), 3291-3299, 2019 | 303 | 2019 |
| Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients AR Mato, BT Hill, N Lamanna, PM Barr, CS Ujjani, DM Brander, C Howlett, ... Annals of Oncology 28 (5), 1050-1056, 2017 | 282 | 2017 |
| T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy G Ghilardi, JA Fraietta, JN Gerson, VM Van Deerlin, JJD Morrissette, ... Nature medicine 30 (4), 984-989, 2024 | 259 | 2024 |
| Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience AR Mato, C Nabhan, PM Barr, CS Ujjani, BT Hill, N Lamanna, ... Blood, The Journal of the American Society of Hematology 128 (18), 2199-2205, 2016 | 235 | 2016 |
| Front‐line, dose‐escalated immunochemotherapy is associated with a significant progression‐free survival advantage in patients with double‐hit lymphomas: a systematic review … C Howlett, SJ Snedecor, DJ Landsburg, J Svoboda, EA Chong, ... British journal of haematology 170 (4), 504-514, 2015 | 214 | 2015 |
| Long-term outcomes from a randomized dose optimization study of chimeric antigen receptor modified T cells in relapsed chronic lymphocytic leukemia NV Frey, S Gill, EO Hexner, S Schuster, S Nasta, A Loren, J Svoboda, ... Journal of Clinical Oncology 38 (25), 2862-2871, 2020 | 195 | 2020 |
| Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States AR Mato, M Thompson, JN Allan, DM Brander, JM Pagel, CS Ujjani, ... Haematologica 103 (9), 1511, 2018 | 193 | 2018 |
| EBV PCR in the diagnosis and monitoring of posttransplant lymphoproliferative disorder: results of a two-arm prospective trial DE Tsai, L Douglas, C Andreadis, DT Vogl, S Arnoldi, R Kotloff, ... American journal of transplantation 8 (5), 1016-1024, 2008 | 192 | 2008 |
| Pembrolizumab for B-cell lymphomas relapsing after or refractory to CD19-directed CAR T-cell therapy EA Chong, C Alanio, J Svoboda, SD Nasta, DJ Landsburg, SF Lacey, ... Blood, The Journal of the American Society of Hematology 139 (7), 1026-1038, 2022 | 191 | 2022 |
| Atorvastatin for anthracycline-associated cardiac dysfunction: the STOP-CA randomized clinical trial TG Neilan, T Quinaglia, T Onoue, SS Mahmood, ZD Drobni, HK Gilman, ... Jama 330 (6), 528-536, 2023 | 187 | 2023 |
| NCCN guidelines® insights: B-cell lymphomas, version 5.2021: featured updates to the NCCN guidelines AD Zelenetz, LI Gordon, JE Chang, B Christian, JS Abramson, RH Advani, ... Journal of the National Comprehensive Cancer Network 19 (11), 1218-1230, 2021 | 158 | 2021 |
| Outcomes of patients with relapsed/refractory diffuse large B‐cell lymphoma with progression of lymphoma after autologous stem cell transplantation in the rituximab era SJ Nagle, K Woo, SJ Schuster, SD Nasta, E Stadtmauer, R Mick, ... American journal of hematology 88 (10), 890-894, 2013 | 158 | 2013 |
| Outcomes of adults and children with primary mediastinal B‐cell lymphoma treated with dose‐adjusted EPOCH‐R L Giulino‐Roth, T O'Donohue, Z Chen, NL Bartlett, A LaCasce, ... British journal of haematology 179 (5), 739-747, 2017 | 153 | 2017 |
| Five-year follow-up of lenalidomide plus rituximab as initial treatment of mantle cell lymphoma J Ruan, P Martin, P Christos, L Cerchietti, W Tam, B Shah, SJ Schuster, ... Blood, The Journal of the American Society of Hematology 132 (19), 2016-2025, 2018 | 142 | 2018 |
| Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre … CS Diefenbach, F Hong, RF Ambinder, JB Cohen, MJ Robertson, ... The Lancet Haematology 7 (9), e660-e670, 2020 | 136 | 2020 |
| R‐CHOP versus dose‐adjusted R‐EPOCH in frontline management of primary mediastinal B‐cell lymphoma: a multi‐centre analysis NN Shah, A Szabo, SF Huntington, N Epperla, N Reddy, S Ganguly, ... British journal of haematology 180 (4), 534-544, 2018 | 122 | 2018 |
